Trait and disease are two different answers from the same test. One copy of the sickle variant produces sickle cell trait. Two copies, or one sickle copy paired with another beta globin variant, produces sickle cell disease, which needs ongoing care directed by a clinician.
Hemoglobin is the oxygen carrying protein packed inside red blood cells, built from four globin chains, each holding an iron containing heme group. Adults make mostly hemoglobin A, with a small amount of hemoglobin A2 and traces of fetal hemoglobin F left over from early life.
A sickle cell test is really a question about which globin chains a person builds, because the sickle variant comes from a single change in the beta globin gene that changes the behaviour of the molecule once it releases oxygen. The hemoglobin biomarker guide linked above covers what the marker measures, how it is tested and how to read a standard hemoglobin result, so the rest of this page stays on the sickle question.
A sickle cell test looks for hemoglobin S, and for how much of it sits alongside normal adult hemoglobin A. The analysis separates the hemoglobin types in a blood sample by their physical and chemical properties, then reports which types are present and roughly what share of total hemoglobin each one makes up.
The mechanism behind the test is simple. The sickle variant swaps one amino acid in the beta globin chain, which gives the molecule a slightly different electrical charge and a sticky patch on its surface. That charge difference is what lets a laboratory pull hemoglobin S away from hemoglobin A on a column or in an electric field. The sticky patch is what matters clinically, because deoxygenated hemoglobin S molecules link into long fibres that stiffen the red cell and distort its shape.
So the report is not a yes or no answer. It is a pattern. A result showing hemoglobin A as the dominant fraction with a smaller hemoglobin S fraction reads very differently from a result showing hemoglobin S with no hemoglobin A at all. The same sample often also reports hemoglobin A2 and hemoglobin F, because those fractions help a laboratory work out whether a thalassemia variant has been inherited alongside the sickle one. Interpreting the whole pattern, not one line of it, is the job of the clinician who ordered the test.
Sickle cell trait means one copy of the sickle beta globin variant and one normal copy, so the body still produces plenty of normal hemoglobin A. Sickle cell disease means no normal beta globin output at all, either from two sickle copies or from one sickle copy inherited with a second beta globin variant such as hemoglobin C or a beta thalassemia variant.
That difference in gene copies shows up directly in the laboratory pattern. In trait, hemoglobin A is the larger fraction and hemoglobin S the smaller one, and the red cells behave normally under ordinary conditions because enough normal hemoglobin is present to keep the sickle molecules from forming fibres. In sickle cell disease, there is no hemoglobin A to dilute the sickle molecules, so the red cells undergo repeated distortion, break down early, and can block small blood vessels. That is the origin of the chronic anemia, pain episodes and organ strain that define the disease.
The practical consequence is that trait is a carrier state, not a mild version of the disease, and the two should never be recorded as the same thing. Studies indicate that trait results are frequently misunderstood by patients and by clinicians who do not work with haemoglobinopathies often, with social, insurance and employment consequences that follow from the confusion 1. If a result in your own records simply says positive for sickle cell, it is worth asking the ordering clinician which pattern the laboratory actually reported.
The methods that reliably identify sickle hemoglobin all separate hemoglobin fractions and measure them, rather than just detecting that something sickles. High performance liquid chromatography, capillary electrophoresis and isoelectric focusing are the usual workhorses, with gel electrophoresis at alkaline and acid pH still used in some laboratories, and DNA analysis reserved for cases the protein methods cannot settle.
A British Society for Haematology guideline describes screening and diagnosis of significant haemoglobinopathies as a staged laboratory process, in which a primary separation method is paired with a second, complementary method before a variant is reported as confirmed 2. The reason is that several hemoglobin variants travel to similar positions on any single method, and a variant that mimics hemoglobin S on one system usually separates cleanly on another.
DNA based testing answers a different question. It identifies the specific variants in the beta globin gene and the surrounding region, which matters when a protein result is ambiguous, when a recent transfusion has muddied the sample, or when a sickle beta thalassemia combination is suspected. Approaches to large scale screening differ between health systems, and population screening for haemoglobinopathies rests on laboratory confirmation paired with counselling rather than on a single test result standing alone 3.
When you book a test, the useful question to ask the ordering clinician or the laboratory is which method will be used and whether the result will distinguish trait from disease. Some requests are filled with a simple screen that cannot.
A solubility screen tells you that sickle hemoglobin is present, and nothing more. It works by breaking red cells open in a solution that removes oxygen, so any hemoglobin S present forms fibres and turns the mixture cloudy. Cloudy means sickle hemoglobin is somewhere in the sample.
What it cannot do is tell you how much. A person with sickle cell trait and a person with sickle cell disease both turn the solution cloudy, so the screen cannot separate the carrier state from the disease, and it cannot identify hemoglobin C, beta thalassemia variants or the many other variants that change how a sickle result should be read. It can also read falsely negative when the sickle hemoglobin fraction is low, for example after a recent transfusion that has filled the circulation with donor red cells. The British Society for Haematology guideline positions solubility testing as an adjunct rather than a standalone diagnostic method, with definitive identification resting on fraction separating techniques 2.
This matters for adults who were tested years ago in a school, workplace or sports setting and remember only that the test was positive or negative. A negative solubility screen from an unknown laboratory, with no record of method or hemoglobin fractions, is not much to go on. A positive one with no follow up leaves the most important question, trait or disease, unanswered. If your status influences family planning decisions or sports clearance, it is reasonable to ask for a result that names the hemoglobin fractions.
The blood draw itself takes a few minutes, and the waiting time for the result depends entirely on the laboratory and the method used. Separation methods are run on analysers that process samples in batches, so the turnaround is shaped by how often that laboratory runs its haemoglobinopathy batch, whether the sample has to be shipped to a reference laboratory, and whether a second confirmatory method or DNA analysis is needed.
Because that varies so much, the reliable way to plan is to ask the ordering clinic or laboratory for its current posted turnaround for this specific test rather than relying on a general estimate. Ask separately about the confirmation step, since an initial report flagged as a presumptive variant may still be waiting on a second method.
Testing outside a central laboratory is a different situation. Research suggests that point of care devices can identify sickle hemoglobin from a small blood sample without a full laboratory analyser, which has been developed mainly for settings where a reference laboratory is far away or unavailable 4. A rapid result is still a screening result, and a positive or ambiguous one leads back to laboratory confirmation.
One more practical note. The test does not need fasting and is not affected by time of day, so scheduling is flexible. What does matter is your transfusion history, which is covered further down, because recent transfused red cells can make a sample unrepresentative of the hemoglobin you actually produce.
Most sickle cell test reports fall into a handful of recognisable patterns, and each one is read by comparing which hemoglobin types are present with how large each fraction is. The table below summarises the patterns an adult is most likely to see on a report.
| Result pattern | What the laboratory report usually shows | What it may reflect |
|---|---|---|
| HbAA | Hemoglobin A present, no hemoglobin S detected | No sickle variant found by that method |
| HbAS | Both hemoglobin A and hemoglobin S, with hemoglobin A the larger fraction | Sickle cell trait, one sickle copy inherited |
| HbSS | Hemoglobin S present with no hemoglobin A, hemoglobin F often raised | Sickle cell anemia, the most common form of sickle cell disease |
| HbSC | Hemoglobin S and hemoglobin C, no hemoglobin A | A form of sickle cell disease |
| HbS with beta thalassemia | Hemoglobin S with reduced or absent hemoglobin A and a raised hemoglobin A2 | Sickle beta thalassemia, a form of sickle cell disease |
| Hemoglobin S plus another variant | Hemoglobin S with an unidentified band or peak | Needs a second method or DNA analysis before it is reported as confirmed |
Pattern names are shorthand, not diagnoses. The same letters can be reported slightly differently by different analysers, and the clinical meaning depends on the full blood count, the red cell indices and the person in front of the clinician. A trait pattern in someone with a normal blood count reads differently from the same pattern in someone with unexplained anemia, because the anemia then needs its own explanation rather than being attributed to the trait.
The practical next step after any pattern other than HbAA is a conversation with the clinician who ordered the test, who can confirm what was measured, whether a confirmatory method was run, and what, if anything, follows.
Several everyday situations can distort the hemoglobin fractions a laboratory measures, which is why a result is always read alongside a full blood count and a short history. The three that come up most often are a recent blood transfusion, iron deficiency, and the co-inheritance of another globin variant.
A recent transfusion is the clearest example. Donor red cells carry donor hemoglobin, so a sample drawn soon after a transfusion reports a blend of two people and can mask or dilute a variant. Iron deficiency is subtler. It lowers the hemoglobin A2 fraction, and because a raised hemoglobin A2 is one of the signals used to spot a beta thalassemia variant inherited alongside the sickle one, low iron stores can make that combination harder to see. Co-inherited alpha thalassemia changes red cell indices in its own direction and shifts the picture again. A review of lessons learnt in haemoglobinopathy screening and diagnosis highlights how transfusion, iron status and co-inherited variants complicate interpretation and why laboratories pair methods and repeat samples rather than reporting a single run 5.
Other factors are more mundane. Sample labelling errors, long transit times in heat, and testing performed with a method that cannot resolve similar variants all produce results that look clean but are not. Some medicines can also affect red cell production and blood counts, so mention everything you take to your prescriber before testing rather than assuming it is irrelevant.
None of this makes the test unreliable. It means a surprising result is usually repeated, and that repetition is good laboratory practice rather than a sign that something has gone wrong.
A trait result means you are a carrier, and most adults with sickle cell trait live without symptoms from it. That is the headline, and it should not be softened into either reassurance that nothing about it matters or alarm that it behaves like the disease.
A systematic review of clinical outcomes found that sickle cell trait is associated with a higher risk of certain specific outcomes, including kidney related findings and exertional rhabdomyolysis, while not being associated with others such as all cause mortality 6. The kidney signal is the most consistently reported. A systematic review and meta analysis of adults with sickle cell trait reported higher odds of chronic kidney disease compared with adults without the trait 7, and an earlier analysis in African American adults found that sickle cell trait is associated with chronic kidney disease and albuminuria 8.
The mechanism offered for the kidney findings relates to the inner medulla of the kidney, an environment that is low in oxygen, concentrated and acidic, which is exactly the combination that encourages sickle hemoglobin to form fibres even when the overall fraction is small.
What this means in practice is modest and specific. Knowing your trait status gives a clinician context when interpreting kidney markers, visible or microscopic blood in the urine, or an episode of collapse during very heavy exertion. It does not make you a patient. Any decision about additional monitoring belongs to the clinician who knows your full history, and a trait result is not a reason to attribute an unrelated symptom to your hemoglobin.
Athletes get screened because the conditions of maximal exertion, low oxygen, rising acidity, heat and dehydration, are the conditions under which sickle hemoglobin is most likely to form fibres, and because collapse during intense exertion is the scenario in which trait status changes how a medical team thinks. Some athletic organisations require athletes to know their status before competition, while others rely on precautions applied to every athlete regardless of status.
That split reflects a genuine disagreement. A review of sickle cell trait screening in sport weighed the costs and benefits of a screening requirement against a universal precautions approach, noting arguments on both sides about which better protects athletes and about the risk of stigma or exclusion following a positive result 9. The counselling that should accompany a positive result is also the part most often missed, and misinformed handling of a trait result carries its own social cost 1.
For an individual adult training hard, the useful version of this is narrow. Knowing your status means a sports medicine clinician can build exertion guidance and heat precautions around a known factor rather than guessing, and it means that if you ever collapse during a session, the people caring for you have one more piece of information. It is not a reason to stop training, and sickle cell trait does not by itself disqualify anyone from sport. What the right precautions are for you is a conversation with a clinician who knows your training load, not a rule you can read off a web page.
A sickle cell result is genetic information, so it says something about your relatives as well as about you. Sickle cell trait is inherited from one parent, which means that a trait result in an adult implies at least one parent carried the variant, and that full siblings have a meaningful chance of carrying it too.
This is why laboratories and clinicians frame testing as a counselling process rather than a result slip. Population screening for haemoglobinopathies is built around confirmed laboratory identification followed by counselling, because the decisions that follow a positive result belong to the person and their family rather than to the laboratory 3. Where two adults in a relationship want to understand what their combined status means, the information they need is which exact variants each carries, not just whether each tested positive, since a sickle variant paired with a different beta globin variant produces a different picture from two sickle variants.
The social dimension is real and worth naming. Trait results have been mishandled in employment, insurance and community settings, and clear counselling at the point of diagnosis is the main protection against that 1. A genetic counsellor or a clinician experienced with haemoglobinopathies is the right person to walk through what a specific combination of results means, and that conversation is usually brief.
If relatives decide to test, encourage them to ask for a method that reports hemoglobin fractions, so that nobody ends up with another positive screen that cannot distinguish trait from disease.
A sickle cell test is interpreted next to a full blood count, because the hemoglobin fractions and the red cell numbers answer different halves of the same question. The count shows how much hemoglobin is present and what the red cells look like, while the fraction analysis shows which hemoglobin types make up that total.
The markers that typically travel with it are hemoglobin, hematocrit, mean corpuscular volume and mean corpuscular hemoglobin, the reticulocyte count as a measure of how fast new red cells are being produced, and iron studies including ferritin, because iron deficiency shifts the hemoglobin A2 fraction and can obscure a thalassemia variant. Hemoglobin A2 and hemoglobin F are usually quantified in the same run. Platelet and white cell numbers come with the count and sometimes raise separate questions of their own.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Hemoglobin, men | 13 to 17.5 g/dL | 14 to 16 g/dL |
| Hemoglobin, women | 11.5 to 16 g/dL | 12 to 15 g/dL |
These are typical laboratory reference ranges, and ranges vary by laboratory, age and sex, so always read a result against the range printed on your own report. FitScript optimal ranges are optimization targets rather than diagnostic cut offs, and no single hemoglobin value identifies or excludes a sickle variant.
FitScript members have 150+ biomarkers tested per year, with results interpreted by Atlas, FitScript's AI health advisor. A hemoglobin variant analysis is a separate, specialised request that a clinician orders when the history or the blood count calls for it.
Testing is worth considering for any adult who does not know their status and has a reason to want it, which most often means a family history of sickle cell trait or disease, ancestry from a region where the variant is common, an unexplained anemia, a partner result that raises questions, or a sport or occupational setting that asks for it.
Arranging the test is straightforward. A clinician orders a hemoglobin variant analysis, often described on a request form as haemoglobinopathy screening or hemoglobin electrophoresis, alongside a full blood count. A standard venous sample is drawn, no fasting is required, and the laboratory runs the separation method. If the ordering clinic is not sure which method their laboratory uses, asking is reasonable, since a method that only reports whether sickling occurs will not answer the trait versus disease question.
Three things make the result more useful. Tell the clinician about any transfusion in recent months, since that changes how the sample is interpreted. Bring any previous result you have, even a partial one, because a historical fraction pattern can save a repeat test. And ask for the actual fraction values to be recorded in your notes rather than a one word summary, so that the result still means something in ten years.
If an initial report comes back flagged as presumptive or as an unidentified variant, that is normal. A second complementary method, or DNA analysis where protein methods disagree, is how laboratories finish the job 2.
After any result other than a plain HbAA pattern, the next step is a conversation with the clinician who ordered the test, so the full pattern can be confirmed and explained. A trait result usually leads to counselling, a note in your records and little else. A pattern consistent with sickle cell disease leads to specialist referral, because ongoing care is coordinated by clinicians who work with the condition.
Some situations deserve a prompt conversation rather than a routine one. Severe or unusual pain, chest pain or breathlessness, a fever with feeling unwell, visible blood in the urine, or collapse during exertion in a person who knows they carry a sickle variant are all reasons to contact a clinician promptly, and in an emergency to seek urgent care. A result that falls outside the standard range on the accompanying blood count is suboptimal rather than settled, and it is worth discussing rather than filing away.
What this page does not do is tell you what comes next medically. In people with sickle cell disease, care is ongoing and individual, and treatment decisions belong to a licensed provider who has reviewed the whole picture. The same is true of any monitoring a clinician may suggest after a trait result.
This page is educational and is not medical advice. Discuss your results and any treatment decisions with a clinician or licensed provider who can see your full history.
Related reading on FitScript: if the full blood count run alongside your sickle cell test flags a low platelet count, the guide to low platelet symptoms explains what that marker tracks and which follow up questions are worth raising with a clinician.
It shows which hemoglobin types your red blood cells contain and roughly how much of each is present. That pattern is what tells a clinician whether sickle hemoglobin is present, and whether normal adult hemoglobin A is present alongside it. The clinician who ordered the test interprets the full pattern together with your blood count.
The blood draw takes only a few minutes. The wait for the result depends on the laboratory, the method used, and whether a second confirmatory method or DNA analysis is needed, so ask the ordering clinic or laboratory for its current posted turnaround time. Results that need confirmation take longer than the first report suggests.
No. The analysis looks at which hemoglobin types your red cells carry, and food, drink and time of day do not change that. What does matter is a recent blood transfusion, so tell the clinician if you have had one, because donor red cells can make the sample unrepresentative.
No. A full blood count measures how much hemoglobin you have and what your red cells look like, not which hemoglobin types are present. Sickle cell trait usually leaves the count looking ordinary. Identifying the variant requires a hemoglobin variant analysis such as electrophoresis or high performance liquid chromatography.
Look for whether hemoglobin A is present. A pattern with both hemoglobin A and hemoglobin S, with A the larger fraction, points to the carrier state, while a pattern with hemoglobin S and no hemoglobin A points to sickle cell disease. If your record only says positive, ask the ordering clinician which fractions the laboratory reported.
Because very heavy exertion, heat and dehydration are the conditions under which sickle hemoglobin is most likely to cause trouble, and knowing an athlete's status gives a medical team useful context if that athlete ever collapses during a session. Some organisations require status to be known, others apply the same precautions to everyone. A sports medicine clinician decides what precautions suit an individual athlete.
Your genes do not change, so the underlying result does not. A report can still look different between tests because of a recent transfusion, iron deficiency or the method the laboratory used. If two reports disagree, the usual answer is a repeat sample analysed by a complementary method.
Start with the clinician who ordered the test, who can confirm the laboratory pattern and explain what it means for you. A result consistent with sickle cell disease leads to referral to a specialist team, and a carrier result usually leads to a counselling conversation about family members. Any next step, including anything related to treatment, is decided by a licensed provider.